The effect of conditioned medium on the biosynthesis and glycosylation profile of acute phase proteins secreted by the human hepatoma cell line Hep G2 was studied.
Following tissue injury, infection, or various inflammatory processes, a number of normal homeostatic mechanisms are substantially changed.' The characteristic pattern of these alterations is termed the acute phase response and includes changes in the concentration of a number of plasma proteins referred to as acute phase proteins. 1 2 Quantitative changes in acute phase proteins are often accompanied by qualitative alterations of their carbohydrate moieties; this is referred to as microheterogeneity. Two types of microheterogeneity have been distinguished3: major microheterogeneity, which reflects changes in the number of branches on heteroglycan antennary structures; and minor microheterogeneity which includes variations in the sialic acid or fucose content. Affinity electrophoresis with concanvalin A as a ligand has been widely used for the determination of major microheterogeneity of acute phase proteins in serum samples.4r' In this system microheterogeneous forms with biantennary heteroglycans can be separated from forms having tri-and/or tetra-antennary units." For multi- heteroglycan proteins the degree of reactivity with concanavalin A depends on the number of biantennary structures present on the molecule. " Two different types of changes in the glycosylation pattern of acute phase proteins in serum samples were found; type I, characterised by an increase in the relative amount of biantennary over more branched structures (increased concanavalin A reactivity), which is seen in patients with acute inflammatory processes; and type II, with a decrease in the relative amount of biantennary over more branched units (decreased concanavalin A reactivity), which is found in patients with chronic inflammatory disease. 10 A decrease in reactivity with concanavalin A of a number of acute phase proteins, mostly marked for a, acid glycoprotein, which was parallel to the increase of disease activity has been seen in serum samples from patients with RA.8 However, in serum samples from patients with systemic lupus erythematosus (SLE), the reactivity of a, acid glycoprotein with concanavalin A was similar to that seen in serum samples from healthy subjects.7 Serum samples from patients with RA and SLE who had intercurrent infections showed a dramatic increase of reactivity between concanavalin A and a, acid glycoprotein. 7 9 An in vitro system has been developed to study the mechanisms controlling the glycosylation changes of acute phase proteins.'2-'5 With this system we have shown that alterations in the glycosylation of acute phase proteins observed in serum samples result from changes occurring within hepatocytes and are mediated by cytokines such as interleukin 6, transforming growth factor 1, and, to some extent, tumour necrosis factor a. Moreover, the activity of interleukin 6 and transforming growth factor f6 may be modulated by interleukin 1 and tumour necrosis factor a. We have also found that the mechanisms regulating the glycosylation changes of acute phase proteins are independent of mechanisms regulating the gene expression of these proteins.
The monocyte/macrophage plays a central part in the mediation of acute phase response events. Cytokines released by this cell are involved in the regulation of gene expression and alterations of the glycosylation of the acute phase proteins in the liver.' '9 These studies were performed to appraise the capabilities of monocytes isolated from patients with active SLE and RA to affect the glycosylation profile of acute phase proteins in vitro. We evaluated both the spontaneous abilities and the abilities of ex vivo activated monocytes. To characterise the cytokines involved in these processes, we neutralised the inducing activity of cytokines secreted by monocytes using specific antibodies.
Patients and methods

PATIENTS
Heparinised blood was obtained from five patients with active SLE (grade III of activity), eight patients with active RA (grade IV of activity) and seven healthy subjects. SLE and classic RA were diagnosed based on the American Rheumatism Association criteria.20 21 The activity of SLE was assessed according to the Rothfield After subculture, cells were maintained in plastic Petri dishes (35 mm) in Eagle's minimal essential medium with 10% fetal calf serum for five days and then for 24 hours in serum free minimal essential medium supplemented with dexamethasone (1 [tmol/l) and insulin (0-02 U/ml). The Hep G2 cells were then exposed to a 10% solution of CM-LPS(-) and CM-LPS (+) obtained from healthy subjects and patients with SLE and RA, in addition to 20% CM-LPS(+) from healthy subjects treated with antibodies against cytokines. In control cultures cells were exposed to minimal essential medium alone. The cells were then incubated for an additional 72 hours with the replacement of medium (containing conditioned medium) every 24 hours. Analyses were carried out in media collected during the final 24 We have previously shown21 that the increased accumulation of proteinase inhibitor in Hep 3B cell medium was parallel to the increase of newly synthesised 3'S-methionine labelled proteinase inhibitor and the increase in its intracellular mRNA concentration. Thus, the changed accumulation ofproteins in the medium reflects, in general, changes in the rate of their synthesis by the hepatoma cell lines.
DETERMINATION OF PROTEINASE INHIBITOR MICROHETEROGENEITY
Patterns of proteinase inhibitor glycosylation were studied by agarose affinity electro-phoresis with concanavalin A (50 ,umol/l; Sigma Chemical). 26 The area under the precipitate curves was determined by planimetry and the relative amounts of the different microheterogeneous forms were expressed as percentages of the total. A reactivity coefficient for each sample was calculated according to the relation: sum of concanavalin A reactive variants/ concanavalin A non-reactive variant.
All statistical analyses were carried out by the Mann-Whitney test. Table 1 shows changes in the synthesis of the studied proteins by Hep G2 cells exposed to various conditioned medium preparations. CM-LPS(-) and CM-LPS(+) obtained from healthy subjects reduced the synthesis ofalbumin to the same degree. Similarly, there was no significant difference between the effect on albumin production of CM-LPS(-) and CM-LPS(+) obtained from patients with RA and SLE. The total reduction of albumin synthesis by conditioned medium from patients with RA was more pronounced, whereas the reduction by conditioned medium from patients with SLE was less pronounced than the reduction caused by conditioned medium from healthy subjects. CM-LPS(+) obtained from healthy subjects or patients with SLE had stronger effects than the corresponding CM-LPS(-) on the increase of a1-antichymotrypsin and proteinase inhibitor synthesis. In contrast, CM-LPS(-) from patients with RA increased the synthesis of a, antichymotrypsin and pro- 
Results
EFFECT OF CONDITIONED MEDIUM ON SYNTHESIS OF ALBUMIN, aL-ANTICHYMOTRYPSIN AND PROTEINASE INHIBITOR BY THE HEP G2 CELL LINE
CM-LPS(-) CM-LPS(+)
Healthy subjects Table 3 Effect ofspecific antibodies to interleukin 6, la, 113, and tumour necrosisfactor a on induction ofbiosynthesis of acute phase proteins and glycosylation by conditioned medium in Hep G2 cells. Abbreviations as in proteins. These studies have also shown (by indirect measures) that during active SLE there is an impaired spontaneous generation of interleukin 6, interleukin 1, and tumour necrosis factor a by peripheral blood monocytes, and during active RA this activity is enhanced.
We have showni3 14 in vitro that two different human hepatoma cells lines, Hep 3B and Hep G2, show various patterns of alterations of the glycosylation of acute phase proteins on induction with a crude cytokine preparation. The alterations resemble those seen in serum samples from patients with SLE and RA. Using these two lines as a model, we have shown that a number of cytokines in various specific combinations may affect the pattern of glycosylation of proteinase inhibitor, a model positive acute phase protein. Interleukin 6 seems to induce two types of alterations, type I which is seen in patients with acute inflammatory processes and type II which is found in serum samples from patients with chronic inflammatory disease. Transforming growth factor 13 induces only type I alterations, whereas tumour necrosis factor a has only a slight effect on type II changes. Interleukin 1 used alone has no effect on any of the alterations. However, when interleukin 1 was added to interleukin 6, it increased its effect on type I but not on type II changes. In contrast, tumour necrosis factor a added to interleukin 6 potentiated its effect on type II, but not on type I alterations. The addition of either interleukin 1 or tumour necrosis factor a to transforming growth factor ,B inhibited the capabilities for inducing type I alterations. The combination of interleukin 6 with transforming growth factor f3 had an additive effect on inducing type I and the opposite effect on inducing type II glycosylation changes. These data, taken together with the results of changes in the biosynthesis of acute phase proteins by cytokines, strongly suggest that specific subsets of cytokines are responsible for mediating type I and type II alterations in the glycosylation of acute phase proteins in addition to the biosynthesis of these proteins.
In serum samples from patients with SLE with various degrees of disease activity, there are very limited or often no changes in the concentration of acute phase proteins.7 28 Alterations in the glycosylation of acute phase proteins in serum samples are not found in patients with active SLE, whereas patients with SLE with intercurrent infections have a significant increase in the number ofacute phase proteins. 28 Changes in the glycosylation of acute phase proteins (type I) are almost always found in these patients. In contrast, in the course of RA, the whole spectrum of (type II) alterations of acute phase proteins is seen, and the observed changes correlate with the degree of disease activity. 8 9 Intercurrent infections do not have an additive effect on the concentration of acute phase proteins in serum, but have an opposite effect on the alterations (type I) in the glycosylation of acute phase proteins to that which the exacerbation of the disease evokes. 9 These results indicate that differences in the pattern of glycosylation of acute phase proteins observed in patients with active SLE and active RA may be associated with different secretions of the cytokines involved in these processes. This finding suggests that activity of RA, but not SLE, is connected with activation of monocytes.. Moreover, ex vivo activation by lipopolysaccharides of monocytes from patients with SLE corrected their impaired abilities to induce glycosylation alterations of acute phase proteins, indicating that these cells are capable of responding to exogenous inflammatory stimuli. This observation could explain the basis of altered glycosylation of acute phase proteins seen in patients with SLE with intercurrent infections; studies of monocytes isolated from such patients would directly support this hypothesis.
Monocytes secrete a number of cytokines known to be involved in mediating acute phase protein changes. These include interleukin 6, interleukin la and (3, tumour necrosis factor a, and transforming growth factor P3. The monocyte is not, however, the only cell which secretes cytokines mediating these events. Many other cell types can serve as sources of these cytokines, namely platelets, which are source of transforming growth factor 3,29 or fibroblasts which secrete interleukin 6.3 However, fibroblasts, for instance, require interleukin 1 or tumour necrosis factor a for the induction of interleukin 6 production.30 Thus, there is a link between the functional capabilities of monocytes and the activation of other cells, indicating that the defective function of monocytes in paients with SLE may lead to the impaired function of other cells involved in the acute phase response. Accordingly, for a final evaluation, the measurement of various cytokines in serum samples from patients with SLE would be useful. Houssiau et al reported3'
raised levels of interleukin 6 in serum samples from patients with RA, which correlated with the increased concentrations of a number of acute phase proteins in serum. Fong et a132 observed the same phenomenon in serum samples from patients with endotoxaemia.
In these studies using antibodies against various cytokines, we were not able completely to neutralise the effect of conditioned medium on the induction of changes in the glycosylation of acute phase proteins. It is possible that other cytokines secreted either by monocytes or other adherent cells, which might be present in monocyte preparations, are involved in these processes. At the time of these studies, no neutralising antibodies against transforming growth factor 13 were commercially available. However, the effect of transforming growth factor 13 in Hep G2 cells is opposite to the effect of interleukin 6,1' thus the neutralisation of transforming growth factor 13 should lead to the increased effect of interleukin 6. In fact, the human hepatoma cell lines Hep G2 and Hep 3B should be used to gain a better understanding of the effect of conditioned medium on various types of glycosylation changes. However, owing to the limited number of cells obtained from patients, especially patients with SLE, the application of both lines in these studies was impossible.
The so called defective function of monocytes from patients with SLE has been reported, including reduced phagocytic activity, decreased hexose monophosphate shunt and glycolytic activity, and the defective production of interleukin 1.33 34 In contrast, the increased generation of interleukin 1 by monocytes from patients with active RA was found. 35 Franchimont et al have shown36 that peripheral blood mononuclear cells from patients with RA did not spontaneously release tumour necrosis factor a. In our studies we confirmed (by indirect measurements) earlier results of impaired and enhanced generation of interleukin 1 by monocytes from patients with SLE and RA, respectively, and explored the similar effects for interleukin 6 and tumour necrosis factor a.
